Table 2.
Summary of the meta-analysis results.
| Analysis | N | References | Random-effects model | Fixed-effects model | Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | I2 | Ph | |||
| OS | 7 | (9, 10, 12, 14–17) | 2.24 (1.50, 3.35) | 0 | 1.70 (1.43, 2.03) | 0 | 63.3% | 0.012 |
| Subgroup 1: sample size ≥ 200 | 2 | (9, 15) | 1.92 (0.95, 3.88) | 0.07 | 2.30 (1.62, 3.26) | 0 | 82.1% | 0.018 |
| Sample size ≥ 200 | 5 | (10, 12, 14, 16, 17) | 2.56 (1.51, 4.32) | 0 | 1.54 (1.26, 1.89) | 0 | 42.5% | 0.138 |
| Subgroup 2: univariate analysis | 3 | (9, 14, 16) | 3.11 (2.01, 4.80) | 0 | 3.11 (2.01, 4.80) | 0 | 0.0% | 0.692 |
| Multivariate analysis | 4 | (10, 12, 15, 17) | 1.83 (1.19, 2.82) | 0.006 | 1.52 (1.25, 1.84) | 0 | 56.2% | 0.077 |
| Subgroup 3: solid tumor | 5 | (10, 14, 15, 16, 17) | 2.43 (1.31, 4.68) | 0.005 | 1.63 (1.33, 1.99) | 0 | 67.9% | 0.014 |
| Hematological tumor | 2 | (9, 12) | 2.05 (1.08, 3.90) | 0.028 | 2.00 (1.38, 2.90) | 0 | 66.2% | 0.085 |
| Subgroup 4: medium age at diagnosis ≥ 60 | 4 | (12, 14, 16, 17) | 2.61 (1.36, 5.01) | 0.004 | 2.28 (1.58, 3.29) | 0 | 56.7% | 0.074 |
| Medium age at diagnosis ≥60 | 2 | (10, 15) | 1.43 (1.15, 1.77) | 0.001 | 1.43 (1.15, 1.77) | 0.001 | 0.0% | 0.332 |
| PFS | 2 | (11, 16) | 3.90 (2.33, 6.52) | 0 | 3.90 (2.33, 6.52) | 0 | 0.0% | 0.601 |
N, number of studies; HR, hazard ratio; 95% CI, 95% confidence interval; Ph, P values of Q test; OS, overall survival; PFS, progression free survival.